Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — | — | — | — |
| Operating income | -$7.02M | -$5.12M | -$4.56M | -$2.75M | -$1.06M | -$325K | -$658K | -$3.40M | -$3.66M | -$3.43M |
| Net income | -$7.00M | -$5.10M | -$4.55M | -$2.73M | -$1.06M | -$299K | $12.1M | -$3.03M | -$3.34M | -$3.30M |
| EPS (diluted) | -$0.02 | -$0.01 | -$0.01 | -$0.01 | $0.00 | $0.00 | $0.03 | -$0.02 | -$0.02 | -$0.02 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$3.76M | -$2.91M | -$3.71M | -$2.71M | -$825K | -$220K | $11.7M | -$2.70M | -$3.23M | -$3.23M |
| Dividends paid | — | — | — | $99.2K | $0.00 | — | — | — | — | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $6.89M | $344K | $1.11M | $804K | $75.1K | $30.6K | $12.0M | $8.84M | $5.61M | $2.38M |
| Total assets | $7.34M | $768K | $1.23M | $900K | $132K | $58.8K | $12.0M | $8.95M | $5.69M | $2.51M |
| Total liabilities | $308K | $601K | $1.20M | $3.43M | $3.49M | $3.68M | $3.68M | $3.67M | $3.71M | $3.80M |
| Shareholders' equity | $7.03M | $167K | $32.4K | -$2.53M | -$3.36M | -$3.62M | $8.30M | $5.28M | $1.99M | -$1.29M |
| Retained earnings | -$43.2M | -$48.3M | -$53.0M | -$55.9M | -$57.2M | -$57.7M | -$45.8M | -$48.8M | -$52.1M | -$55.4M |
| Shares (wtd avg diluted) | 353M | 370M | 370M | 370M | 374M | 376M | 366M | 172M | 172M | 173M |
Every figure is extracted from Inhibitor Therapeutics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.